Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial brillation and no history of stroke or transient ischemic attacks

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2006, Pages

  Aguilar, Maria I ^a   Hart, R ^b   Pearce, L A ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 [4 (AMINOIMINOMETHYL)PHENYL] 1 PIPERAZINYL] 1 PIPERIDINEACETIC ACID; ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ARGATROBAN; CILOSTAZOL; CLOPIDOGREL; COUMARIN ANTICOAGULANT; CY 222; DEFIBROTIDE; DIPYRIDAMOLE; DISINTEGRIN; ENOXAPARIN; ILOPROST; INDOBUFEN; ISBOGREL; KETANSERIN; KETOROLAC TROMETAMOL; LEVAMISOLE; MILRINONE; MOPIDAMOL; NADROPARIN; OZAGREL; PAMICOGREL; PENTOXIFYLLINE; PICOTAMIDE; PROCAINAMIDE; PROSTACYCLIN; PROSTAGLANDIN E1; SULOCTIDIL; TETRAMETHYLPYRAZINE; THIOPHENE; TICLOPIDINE; TRAPIDIL; TRIFLUSAL; UNINDEXED DRUG; WARFARIN;

BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART INFARCTION; HUMAN; INTERVENTION STUDY; LONG TERM CARE; LOW DRUG DOSE; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PATIENT SELECTION; REVIEW; STROKE; SYSTEMATIC REVIEW; TRANSIENT ISCHEMIC ATTACK; VASCULAR DISEASE;

EID: 42749103136     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006186     Document Type: Review

References (19)

1. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from ve randomized clinical trials. Archives of Internal Medicine 1994;154:1949-57.
2. Aguilar M, Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. In: Cochrane Database of Systematic Reviews, 1, 2006.
3. Aguilar MI, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. In: Cochrane Database of Systematic Reviews, 1, 2006.
4. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. BMC Medical Research Methodology 2001;1:2.
5. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: EggerM, Davey SmithG, AltmanDG editor(s). Systematic reviews in healthcare: meta-analysis in context. 2nd Edition. London: BMJ Books, 2001:285-312.
6. Feinberg WM, Blackshear JL, Laupacis A, Kronmal RA, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Archives of Internal Medicine 1995;155:469-73.
7. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-70.
8. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BSP, et al. Selecting patients with atrial fibrillation for anticoagulation. Stroke risk stratification in patients taking aspirin. Circulation 2004;110:2287-92.
9. Go AS, Hylek EM, Phillips KA, Chang YC, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5.
10. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice. JAMA 2003;290:2685-92.
11. Hart RG, Pearce L, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: Analysis of 2012 participants in the SPAF I-III clinical trials. Stroke 1999;30:1223-9.
12. Hart RG, Halperin JL, Pearce LA, Anderson DC, Kronmal RA, McBride R, et al. Lessons from the stroke prevention in atrial fibrillation trials. Annals of Internal Medicine 2003;138:831-8.
13. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
14. Hylek EM, Go AS, Chang Y, Jensvold NG, Henaut LE, Selby JV, et al. Effect of oral anticoagulation on stroke severity and mortality in atrial fibrillation. New England Journal of Medicine 2003;349:1019-26.
15. Oden A, Fahlen M, Hart RG. Optimal INR for prevention of stroke and mortality in atrial fibrillation: a critical appraisal. Thrombosis Research 2006;117:493-9.
16. Taylor FC, Cohen H, Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ 2001;322:321-26.
17. Van Walraven C, Hart RG, Singer DE, Laupacis A, Connolly S, Petersen P, et al. Oral anticoagulants vs aspirin on nonvalvular atrial fibrillation. An individual patient meta-analysis. JAMA 2002;288: 2441-8.
18. Wang TJ, Massaro JM, Levy D, Vasan RS, Wolf PA, D'Agostino RB, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community. The Framingham Heart Study. JAMA 2003;290:1049-56.
19. Wolf PA, Abbot RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke 1991;22:983-8.